Table 4

Scenarios: OPAT outpatient versus inpatient stay

ScenarioBase case
0Base case (outpatient)
1Using cost of inpatient care in infectious disease unit (ISD Scotland)14Using condition-specific healthcare resource group costs15
2Using ISD Scotland14 cost for outpatient appointments and inpatient stay (IDU)Using microcosting of nurse and consultant outpatient appointments
3Assuming overheads are 44.8% of total costs consistent with a published source16Assuming per day cost of using healthcare services consistent with a published source8
4Using BNF12 as a source for the cost of linezolid (orthopaedic and diabetic foot infections)Using eMIT13 as a source for the cost of linezolid (orthopaedic and diabetic foot infections)
Skin and soft-tissue infections only
5Including the cost of consultant timeNurse-led condition; no consultant time
6Using the licensed dose of dalbavancin (1.5 g) once offUsing dalbavancin 1 g as a once-off treatment consistent with clinical practice
7Using the licensed dose of dalbavancin 1 g followed by 0.5 gUsing dalbavancin 1 g as a once-off treatment consistent with clinical practice
  • BNF, British National Formulary; eMIT, electronic market information tool; IDU, infectious disease unit; ISD, information services division; OPAT, outpatient parenteral antimicrobial therapy.